A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana,\u00a0on March 17, 2024.<\/p>\n
Scott Olson | Getty Images<\/p>\n
Eli Lilly<\/a> on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.<\/p>\n Shares of the company rose 5% in premarket trading Thursday.<\/p>\n The pharmaceutical giant now expects its fiscal 2025 revenue to come in between $63 billion and $63.5 billion, up from a previous guidance of $60 to $62 billion. Eli Lilly also expects full-year adjusted profit to come in between $23 and $23.70 per share, up from its previous outlook of $21.75 to $23 a share.<\/p>\n Mounjaro raked in $6.52 billion in revenue for the quarter, up 109% from the same period a year ago. That blew past the $5.51 billion that analysts were expecting, according to StreetAccount.\u00a0<\/p>\n Zepbound, which entered the market roughly two years ago, posted $3.57 billion in revenue for the third quarter. That’s up 184% from the year-earlier period and slightly ahead of the $3.5 billion that Wall Street was expecting, according to StreetAccount estimates.<\/p>\n Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:\u00a0<\/p>\n Earnings per share:\u00a0$7.02 adjusted vs. $5.69 expectedRevenue:\u00a0$17.60 billion vs. $16.01 billion expected<\/p>\n The results come as Eli Lilly<\/a> works to maintain its edge over chief rival Novo Nordisk<\/a> in the booming market for a class of obesity and diabetes drugs called GLP-1s.<\/p>\n This story is developing. Please check back for updates.<\/p>\n","protected":false},"excerpt":{"rendered":"A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana,\u00a0on March…\n","protected":false},"author":2,"featured_media":112080,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[2691,2368,14408,72,122,2688,103,397,2690,396,61,60,2689,1691],"class_list":["post-112079","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-biotech-and-pharmaceuticals","tag-biotechnology","tag-breaking-news-business","tag-business","tag-business-news","tag-eli-lilly-and-co","tag-health","tag-health-care","tag-health-care-industry","tag-healthcare","tag-ie","tag-ireland","tag-novo-nordisk-a-s","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/112079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=112079"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/112079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/112080"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=112079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=112079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=112079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}